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Current research aimed at evaluating the in vitro as well as in vivo anticancer activities of a newly synthesized  
peptide hydrazide; i.e. 4,14-diisopropyl-2,5,13,16-tetraoxo-3,6,12,15-tetraaza-1(3,5)-pyridinacyclohexadecaphane-7-
carbohydrazide. The hydrazide was synthesized from methyl 4,14-diisopropyl-2,5,13,16-tetraoxo-3,6,12,15-tetraaza-1(3,5)-
pyridinacyclohexadecaphane-7-carboxylate 2 by acting of hydrazine hydrate. It showed significant anticancer effects against 
different tested cell lines, where cervical, breast, liver, colon, prostate, brain, fibrosarcoma, leukemia and melanoma cell 
lines were the most affected cell types. The prepared derivative also inhibited VEGF-2 kinase enzyme significantly and 
exhibited an in vivo tumorigenic effects in mice model. 
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Introduction 
Hydrazides have been known to be associated with 
Antibacterial1, antifungal (against three species such as: 
Candida albicans, Candida glabrata, and Candida 
tropicalis2), anthelmintic3, and anticonvulsant4 
activities. On the other hand, hydrazide and their 
derivatives "hydrazones" constitute a large class of 
organic candidates, which played very important role 
in medicinal chemistry due to the fact that they contain 
azomethine group (–NH–N=CH–) connected with 
carbonyl group, which is responsible for their different 
pharmaceutical applications and makes possible the 
synthesis of different heterocyclic scaffolds.5 In recent 
years, a lot of biologically important heterocyclic and 
hydrazide derivatives with a number of functional 
groups have been synthesized6–11 from many different 
carbonyl compounds. In addition, they were found to 
possess anticancer12–15, anti-inflammatory16, 
anticonvulsant17, antiviral18, and antiprotozoal19 
activities. The aim of the current work was to 
synthesize a new hydrazide tripeptide as a macrocyclic 
tripeptidopyridine and to evaluate its possible 
anticancer activities in vitro as well as in vivo.  
Materials and Methods 
 
Reagents 
3,5-Pyridinedicarbonylchloride, L-Valene, methanol, 
dichloromethane, hydrazine hydrate, and L-lysine 
methyl ester, were all purchased from Sigma-Aldrich 
(Switzerland). Melting point was determined in Electro 
Thermal Digital melting point apparatus IA9100. IR 
(KBr) spectra were recorded on a Nexus 670 FTIR 
Fourier Transform infrared spectrometer. 1H NMR and 
13C NMR spectra were recorded in DMSO-d6 on a JEOL 
500 MHz instrument (Tokyo, Japan). Mass spectra were 
run on a MAT Finnigan SSQ 7000 spectrometer 
(Shimadzu, Kyoto, Japan; Model: QP2010 ultra), using 
the electron impact technique (EI).  
 
Synthesis of 4,14-diisopropyl-2,5,13,16-tetraoxo-3,6,12,15-
tetraaza-1(3,5)-pyridinacyclo-hexadecaphane-7-
carbohydrazide3 
To a solution of methyl 4,13-diisopropyl- 
2,5,12,15-tetraoxo-3,6,11,14-tetraaza-1(3,5)-pyridin- 
acyclopentadecaphane-7-carboxylate (2) (0.475 g,  
1 mmol) in absolute methanol (25 mL), hydrazine 
hydrate (0.8 mL, 16 mmol) was added with stirring. 
The reaction mixture was heated under reflux for 6 h, 
and then evaporated to dryness under vacuum. The 
formed residue was washed with diethyether  
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several times, filtered off, and crystallized from 
dioxane-water to afford the corresponding 4, 
14-diisopropyl-2,5,13,16-tetraoxo-3,6,12,15-tetraaza-
1(3,5)-pyridinacyclohexadecaphane-7 carbohydrazide3. 
The obtained compound 3 was compared with 
authentic sample previously prepared and 
characterized by Amr et al.20 
 
Anticancer screening  
Serial dilutions of the prepared hydrazide (in 
DMSO) were evaluated for their anticancer activities 
using standard MTT assay following the protocol 
previously developed in our laboratories.21,22 The 
method is based on the reaction between the effector 
and the dehydrogenases within cellular mitochondria. 
Absorbance was measured using a microplate reader 
as 560 nm. Reference drugs were used as positive 
controls depending on tested cell lines. 
 
In vivo evaluation of antiprostate cancer activity 
This section was carried out using Male Wistar rats 
injected with androgensto develop prostate cancer  
in vivo. The assay and measurement protocols were 
adapted from our previous works.23  
 
Mechanism of action studies 
In order to evaluate the possible mechanistic 
pathway, by which the prepared hydrazide may affect 
cancer cells, we investigated the inhibition of vascular 
endothelial growth factor (VEGF receptors). The 
assay was done according to our previously published 
protcools.24 
 
Result and Discussion 
 
Chemistry 
We have previously synthesized some macrocyclic 
tripeptidopyridine candidate3and they characterized 
by physical, chemical and spectroscopic evidences in 
advance according to our previous work.20 Compound 
2 was synthesized by treating ofdiacid chloride 1 with 
L-valine methyl ester to give the corresponding bis-
ester followed by hydrolysis with methanolic sodium 
hydroxide to give the corresponding bis-acid 
derivative. The latter compound was cyclized with L-
lysine methyl ester hydrochloride by using mixed 
anhydride method gave cyclized product 2. Treatment 
of 2 with hydrazine hydrate in methanol gave the 
corresponding hydrazide 3 (Scheme 1). 
 
In vitro anticancer evaluation 
The present section aimed at investigation the 
possible anticancer effects of the synthesized derivative 
(compound 3) against various cancer cell lines. Results 
in Fig. 1 showed clearly that the prepared compound 
have an anticancer effect against all tested cell lines 
and also in a dose-dependent relationship. However, 
the effect varied depending on the tested cell line. This 
is in great accordance with our previously published 
work on the evaluation of anticancer potential of 
synthesized molecules.22,24,25 This effect can be 
attributed to the varied architecture of membrane 
structure of various cell types. Secondly, it can be seen 
that comparing the obtained anticancer effects with 
standard pharmaceutical drugs, which are usually used 
in clinical studies as well as scientific research, showed 
that the tested cell lines can be divided into two main 
categories, in terms of their response to compound 5. 
The first class, where the cells were affected, however, 
with a lower potential than the tested drugs, includes 
SKOV3 (ovarian), NCIH460 (non-small lung cancer), 
HL50 and U937 (leukemia), GOTO and NB1 
(melanoma) cell lines. It can be seen that the reported 
IC50 values for were lower than the values obtained for 
positive drugs by about 1.1-, 1.25-, 4.8-, 1.5-, 1.58- and 
1.28-folds for SKOV3, NCIH460, HL60, U937, 
GOTO and NB1 cells, respectively. 
On the other hand, the remaining tested cell lines 
were affected with higher degrees of biological 
activities, where the obtained IC50 values (0.45, 4.56, 
1.45, 2.67, 5.43, 1.24, 0.45, 2.0, 1.0, 2.0 and 5.99 nM) 
were higher by about 9.9-, 1.7-, 2.99-, 2.5-, 1.23-, 2.8-
, 26.2-, 1.1-, 13.4-, 1.72- and 1.4-folds for KB 
(cervical), SF268 (CNS), RKOP27 (colon), K561 
(leukemia), G361 (melanoma), SKMEL28 
(melanoma), HeLa (cervical), MCF7 (breast), 
HT1080 (fibrosarcoma)), HepG2 (liver) and PC3 
(prostate) cells, respectively. The values recorded for 
their corresponding positive drugs were 4.46, 7.68, 
4.33, 6.66, 6.66, 3.45, 11.8, 2.22, 13.24, 3.44 and 8.22 
nM for Florouracil, Cytarabine, Capecitabine, 
Doxorubicin, Aldesleukin, Aldesleukin, Paclitaxel, 
Epirubicin, Imatinib, Gemcitabine and Bicalutamide, 
respectively, for the same order of cell lines.  
 
In vivo anticancer potential 
The second section was designed to investigate the 
potential of compound 3 to affect the growing tumor 
of prostate cancer in vivo in animal model. Results 
obtained showed that the synthesized derivative 
potentially decreased the in vivo prostate tumor 
growth by an ED50 value of 1.28 ± 0.032 μM. It can 
be seen that this value is significant when compared 
to that obtained for Flutamide as a positive drug  
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Scheme 1— Synthetic pathway for compound 3 
 
  
Fig. 1 — Effect of compound 3 on the viability of different tested cancer cell lines 
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(11.60 ± 0.09 μM), where the in vivo effect increased 
by about 8839% from the positive control. 
 
Mechanism of action investigation 
Finally, the inhibition of the receptors for vascular 
endothelial growth factor-2 was evaluated in response 
to different concentrations of the prepared derivative. 
Results showed that the kinase enzyme was 
significantly inhibited at an IC50 of 1.02 nM, when 
compared to the value obtained for reference drug 
inhibition (Sorafenib, IC50 = 2 nM). These results 
suggest that the prepared compound 5 may exhibit its 
anticancer activity via blocking the receptors for 
VEGF-2 kinase enzymatic pathway. 
 
Conclusion 
Within the framework of our continuing efforts to 
provide the pharmaceutical industry with biologically 
active molecules exhibiting potential anticancer 
activities against a wide range of tumorigenic cell 
lines, we prepared a Cyclo (Nα-dinicotinoyl)-bis-[(L-
valinyl)-L-lysinyl acid hydrazide] via hydrazonolysis 
mechanism. The prepared acid hydrazide showed 
great potential against all tested cell lines. 
Furthermore, the effect was cell line-dependent. HeLa 
and HT1080 cells were affected by about 26.2- and 
13.4-folds higher that the evaluated positive 
references. Additionally, results showed that the 
prepared hydrazide has a potential in vivo anticancer 
activity, and that these in vitro as well as in vivo 
biological effects may be related to the inhibition of 
cell receptors for VEGF-2 kinase enzyme. 
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